Drugs / PTH1-84 mRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07197450 | May 2025 → Jul 2026 overdue | hypoparathyroidism | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTH1-84 mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197450 ↗ |
| Action | Restore | “a novel PTH replacement therapy drug” NCT07197450 ↗ |
| Modality | Messenger RNA (mRNA) | “The drug is an mRNA drug” NCT07197450 ↗ |
| Route | Intravenous | “intravenous administration of PTH1-84 mRNA” NCT07197450 ↗ |